STOCK TITAN

[SCHEDULE 13G/A] Arcturus Therapeutics Holdings Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary

Schedule 13G/A (Amendment 8) filed on 07/30/2025 discloses that ARK Investment Management LLC and its CEO/CIO Catherine D. Wood collectively hold a significant position in Arcturus Therapeutics Holdings Inc. (ARCT).

  • Shares beneficially owned: 1,715,040 common shares.
  • Ownership percentage: 6.32 % of ARCT’s outstanding stock.
  • Voting & dispositive power: ARK has sole voting and dispositive power over the full position; Wood has shared power through her control of ARK.
  • Form type of filer: ARK is an investment adviser (IA); Wood is reported as a holding-company/control person (HC, IN).
  • Client concentration: The ARK Genomic Revolution ETF is the only ARK client with an interest >5 % of ARCT.

The filing states the shares were acquired and are held in the ordinary course of business and not with the intent to influence control of the issuer.

Schedule 13G/A (Emendamento 8) presentato il 30/07/2025 rivela che ARK Investment Management LLC e la sua CEO/CIO Catherine D. Wood detengono congiuntamente una posizione significativa in Arcturus Therapeutics Holdings Inc. (ARCT).

  • Azioni detenute: 1.715.040 azioni ordinarie.
  • Percentuale di proprietà: 6,32% del capitale sociale in circolazione di ARCT.
  • Potere di voto e dispositive: ARK detiene il potere di voto e dispositive esclusivo sull'intera posizione; Wood detiene un potere condiviso tramite il suo controllo su ARK.
  • Tipologia del soggetto che presenta il modulo: ARK è un consulente per investimenti (IA); Wood è indicata come persona di controllo/holding company (HC, IN).
  • Concentrazione clienti: L'ETF ARK Genomic Revolution è l'unico cliente ARK con un interesse superiore al 5% in ARCT.

Il documento dichiara che le azioni sono state acquisite e sono detenute nell'ordinario corso degli affari e non con l'intento di influenzare il controllo dell'emittente.

Schedule 13G/A (Enmienda 8) presentada el 30/07/2025 revela que ARK Investment Management LLC y su CEO/CIO Catherine D. Wood poseen conjuntamente una posición significativa en Arcturus Therapeutics Holdings Inc. (ARCT).

  • Acciones beneficiarias: 1.715.040 acciones ordinarias.
  • Porcentaje de propiedad: 6,32% del capital social en circulación de ARCT.
  • Poder de voto y disposición: ARK tiene el poder exclusivo de voto y disposición sobre toda la posición; Wood tiene poder compartido a través de su control de ARK.
  • Tipo de presentador: ARK es un asesor de inversiones (IA); Wood está reportada como persona de control/holding (HC, IN).
  • Concentración de clientes: El ETF ARK Genomic Revolution es el único cliente de ARK con un interés superior al 5% en ARCT.

La presentación indica que las acciones fueron adquiridas y se mantienen en el curso ordinario del negocio y no con la intención de influir en el control del emisor.

Schedule 13G/A (수정 8)가 2025년 7월 30일 제출되었으며, ARK Investment Management LLC와 그 CEO/CIO Catherine D. Wood가 Arcturus Therapeutics Holdings Inc. (ARCT)에서 공동으로 상당한 지분을 보유하고 있음을 공개합니다.

  • 실질 보유 주식 수: 1,715,040 보통주.
  • 소유 비율: ARCT 발행 주식의 6.32%.
  • 의결권 및 처분 권한: ARK는 전체 지분에 대해 단독 의결권 및 처분 권한을 가지며, Wood는 ARK의 통제를 통해 공동 권한을 가집니다.
  • 신고자 유형: ARK는 투자 자문사(IA)이며, Wood는 지주회사/통제 인물(HC, IN)로 보고되었습니다.
  • 고객 집중도: ARK Genomic Revolution ETF가 ARCT 지분 5% 이상을 보유한 유일한 ARK 고객입니다.

신고서에는 주식이 정상적인 사업 과정에서 취득 및 보유되었으며, 발행인의 지배권에 영향을 미치려는 의도가 없음을 명시하고 있습니다.

Schedule 13G/A (Amendement 8) déposé le 30/07/2025 révèle que ARK Investment Management LLC et sa CEO/CIO Catherine D. Wood détiennent conjointement une position significative dans Arcturus Therapeutics Holdings Inc. (ARCT).

  • Actions détenues bénéficiaires : 1 715 040 actions ordinaires.
  • Pourcentage de détention : 6,32 % des actions en circulation de ARCT.
  • Pouvoir de vote et de disposition : ARK détient le pouvoir exclusif de vote et de disposition sur l'intégralité de la position ; Wood dispose d'un pouvoir partagé via son contrôle d'ARK.
  • Type de déclarant : ARK est un conseiller en investissement (IA) ; Wood est déclarée comme personne de contrôle/holding (HC, IN).
  • Concentration des clients : L'ETF ARK Genomic Revolution est le seul client d'ARK détenant plus de 5 % d'ARCT.

Le dépôt précise que les actions ont été acquises et sont détenues dans le cours normal des affaires et pas dans l'intention d'influencer le contrôle de l'émetteur.

Schedule 13G/A (Änderung 8), eingereicht am 30.07.2025, offenbart, dass ARK Investment Management LLC und deren CEO/CIO Catherine D. Wood gemeinsam eine bedeutende Position an Arcturus Therapeutics Holdings Inc. (ARCT) halten.

  • Vorteilhaft gehaltene Aktien: 1.715.040 Stammaktien.
  • Eigentumsanteil: 6,32 % der ausstehenden Aktien von ARCT.
  • Stimm- und Verfügungsrechte: ARK besitzt alleinige Stimm- und Verfügungsrechte über die gesamte Position; Wood hat geteilte Rechte durch ihre Kontrolle über ARK.
  • Art des Einreichers: ARK ist ein Investmentberater (IA); Wood wird als Holding-/Kontrollperson (HC, IN) gemeldet.
  • Kundenkonzentration: Der ARK Genomic Revolution ETF ist der einzige ARK-Kunde mit einem Anteil von über 5 % an ARCT.

Die Einreichung besagt, dass die Aktien im normalen Geschäftsverlauf erworben und gehalten werden und nicht mit der Absicht, die Kontrolle über den Emittenten zu beeinflussen.

Positive
  • ARK Investment Management and Catherine D. Wood disclose a 6.32 % stake (1.715 M shares) in ARCT, underscoring continued institutional ownership.
Negative
  • None.

Insights

TL;DR: ARK still owns 6.3 % of ARCT; disclosure is routine, confirming continued institutional backing without signaling strategy change.

The amendment shows ARK and Cathie Wood retain 1.72 M shares, equal to 6.32 % of the float—above the 5 % threshold that triggers a Schedule 13G filing. All voting and dispositive power resides with ARK, aligning with its role as investment adviser; Wood’s shared power reflects her control position. No new purchase or sale data is provided, so the filing is largely administrative. For investors, the key takeaway is that a high-profile growth-oriented manager remains a >5 % holder, which may be viewed as supportive of market perception but does not, on its own, alter ARCT’s fundamentals or near-term outlook.

Schedule 13G/A (Emendamento 8) presentato il 30/07/2025 rivela che ARK Investment Management LLC e la sua CEO/CIO Catherine D. Wood detengono congiuntamente una posizione significativa in Arcturus Therapeutics Holdings Inc. (ARCT).

  • Azioni detenute: 1.715.040 azioni ordinarie.
  • Percentuale di proprietà: 6,32% del capitale sociale in circolazione di ARCT.
  • Potere di voto e dispositive: ARK detiene il potere di voto e dispositive esclusivo sull'intera posizione; Wood detiene un potere condiviso tramite il suo controllo su ARK.
  • Tipologia del soggetto che presenta il modulo: ARK è un consulente per investimenti (IA); Wood è indicata come persona di controllo/holding company (HC, IN).
  • Concentrazione clienti: L'ETF ARK Genomic Revolution è l'unico cliente ARK con un interesse superiore al 5% in ARCT.

Il documento dichiara che le azioni sono state acquisite e sono detenute nell'ordinario corso degli affari e non con l'intento di influenzare il controllo dell'emittente.

Schedule 13G/A (Enmienda 8) presentada el 30/07/2025 revela que ARK Investment Management LLC y su CEO/CIO Catherine D. Wood poseen conjuntamente una posición significativa en Arcturus Therapeutics Holdings Inc. (ARCT).

  • Acciones beneficiarias: 1.715.040 acciones ordinarias.
  • Porcentaje de propiedad: 6,32% del capital social en circulación de ARCT.
  • Poder de voto y disposición: ARK tiene el poder exclusivo de voto y disposición sobre toda la posición; Wood tiene poder compartido a través de su control de ARK.
  • Tipo de presentador: ARK es un asesor de inversiones (IA); Wood está reportada como persona de control/holding (HC, IN).
  • Concentración de clientes: El ETF ARK Genomic Revolution es el único cliente de ARK con un interés superior al 5% en ARCT.

La presentación indica que las acciones fueron adquiridas y se mantienen en el curso ordinario del negocio y no con la intención de influir en el control del emisor.

Schedule 13G/A (수정 8)가 2025년 7월 30일 제출되었으며, ARK Investment Management LLC와 그 CEO/CIO Catherine D. Wood가 Arcturus Therapeutics Holdings Inc. (ARCT)에서 공동으로 상당한 지분을 보유하고 있음을 공개합니다.

  • 실질 보유 주식 수: 1,715,040 보통주.
  • 소유 비율: ARCT 발행 주식의 6.32%.
  • 의결권 및 처분 권한: ARK는 전체 지분에 대해 단독 의결권 및 처분 권한을 가지며, Wood는 ARK의 통제를 통해 공동 권한을 가집니다.
  • 신고자 유형: ARK는 투자 자문사(IA)이며, Wood는 지주회사/통제 인물(HC, IN)로 보고되었습니다.
  • 고객 집중도: ARK Genomic Revolution ETF가 ARCT 지분 5% 이상을 보유한 유일한 ARK 고객입니다.

신고서에는 주식이 정상적인 사업 과정에서 취득 및 보유되었으며, 발행인의 지배권에 영향을 미치려는 의도가 없음을 명시하고 있습니다.

Schedule 13G/A (Amendement 8) déposé le 30/07/2025 révèle que ARK Investment Management LLC et sa CEO/CIO Catherine D. Wood détiennent conjointement une position significative dans Arcturus Therapeutics Holdings Inc. (ARCT).

  • Actions détenues bénéficiaires : 1 715 040 actions ordinaires.
  • Pourcentage de détention : 6,32 % des actions en circulation de ARCT.
  • Pouvoir de vote et de disposition : ARK détient le pouvoir exclusif de vote et de disposition sur l'intégralité de la position ; Wood dispose d'un pouvoir partagé via son contrôle d'ARK.
  • Type de déclarant : ARK est un conseiller en investissement (IA) ; Wood est déclarée comme personne de contrôle/holding (HC, IN).
  • Concentration des clients : L'ETF ARK Genomic Revolution est le seul client d'ARK détenant plus de 5 % d'ARCT.

Le dépôt précise que les actions ont été acquises et sont détenues dans le cours normal des affaires et pas dans l'intention d'influencer le contrôle de l'émetteur.

Schedule 13G/A (Änderung 8), eingereicht am 30.07.2025, offenbart, dass ARK Investment Management LLC und deren CEO/CIO Catherine D. Wood gemeinsam eine bedeutende Position an Arcturus Therapeutics Holdings Inc. (ARCT) halten.

  • Vorteilhaft gehaltene Aktien: 1.715.040 Stammaktien.
  • Eigentumsanteil: 6,32 % der ausstehenden Aktien von ARCT.
  • Stimm- und Verfügungsrechte: ARK besitzt alleinige Stimm- und Verfügungsrechte über die gesamte Position; Wood hat geteilte Rechte durch ihre Kontrolle über ARK.
  • Art des Einreichers: ARK ist ein Investmentberater (IA); Wood wird als Holding-/Kontrollperson (HC, IN) gemeldet.
  • Kundenkonzentration: Der ARK Genomic Revolution ETF ist der einzige ARK-Kunde mit einem Anteil von über 5 % an ARCT.

Die Einreichung besagt, dass die Aktien im normalen Geschäftsverlauf erworben und gehalten werden und nicht mit der Absicht, die Kontrolle über den Emittenten zu beeinflussen.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



ARK Investment Management LLC
Signature:/s/ Kellen Carter
Name/Title:Kellen Carter, Chief Compliance Officer
Date:07/30/2025
Catherine D. Wood
Signature:/s/ Catherine D. Wood
Name/Title:Catherine D. Wood, Chief Executive Officer, Chief Investment Officer
Date:07/30/2025

FAQ

How many Arcturus Therapeutics (ARCT) shares does ARK Investment Management own?

The filing reports 1,715,040 common shares beneficially owned.

What percentage of ARCT's outstanding stock is held by ARK and Cathie Wood?

They collectively own 6.32 % of the common shares.

Who are the reporting persons in the ARCT Schedule 13G/A?

The reporting persons are ARK Investment Management LLC and its CEO/CIO Catherine D. Wood.

What is the effective date of ownership stated in the filing?

The ownership information is stated as of June 30, 2025.

Does Catherine Wood have voting power over the ARCT shares?

Yes. Wood has shared voting and dispositive power over the 1.715 M shares through her control of ARK.

Why was a Schedule 13G/A filed for ARCT?

Because the reporting persons hold more than 5 % of ARCT’s outstanding shares, requiring disclosure under SEC Rule 13d-1.
Arcturus Therape

NASDAQ:ARCT

ARCT Rankings

ARCT Latest News

ARCT Latest SEC Filings

ARCT Stock Data

354.20M
24.98M
8.45%
92.53%
15.52%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN DIEGO